Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

GNC sales increase

This article was originally published in The Tan Sheet

Executive Summary

General Nutrition Centers sales advanced 6.7 percent in 2008 to $1.66 billion, the Pittsburgh-based nutritional supplements retailer announces March 19. Earnings before income taxes, depreciation and amortization for the year were $212.2 million, compared to $125.5 million in 2007, when the firm absorbed a number of costs associated with the 2007 acquisition of the firm's parent company (1"The Tan Sheet" Feb. 12, 2007, p. 9). In the fourth quarter, consolidated revenues increased 4.2 percent to $391.7 million, with growth recorded in each of the firm's business segments. Fourth quarter EBITDA was relatively flat at $45.8 million, the firm says

General Nutrition Centers sales advanced 6.7 percent in 2008 to $1.66 billion, the Pittsburgh-based nutritional supplements retailer announces March 19. Earnings before income taxes, depreciation and amortization for the year were $212.2 million, compared to $125.5 million in 2007, when the firm absorbed a number of costs associated with the 2007 acquisition of the firm's parent company (1 (Also see "GNC To Be Acquired For $1.65 Bil. By Ares, Ontario Teachers’ Pension Plan" - Pink Sheet, 12 Feb, 2007.), p. 9). In the fourth quarter, consolidated revenues increased 4.2 percent to $391.7 million, with growth recorded in each of the firm's business segments. Fourth quarter EBITDA was relatively flat at $45.8 million, the firm says.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS102732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel